AU2015274767B2 - Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof - Google Patents

Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof Download PDF

Info

Publication number
AU2015274767B2
AU2015274767B2 AU2015274767A AU2015274767A AU2015274767B2 AU 2015274767 B2 AU2015274767 B2 AU 2015274767B2 AU 2015274767 A AU2015274767 A AU 2015274767A AU 2015274767 A AU2015274767 A AU 2015274767A AU 2015274767 B2 AU2015274767 B2 AU 2015274767B2
Authority
AU
Australia
Prior art keywords
group
heteroaryl
aryl
cycloalkyl
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015274767A
Other languages
English (en)
Other versions
AU2015274767A1 (en
Inventor
Chaofeng DAI
Krishna DAMERA
Alexander Draganov
Xingyue JI
Didier Merlin
Emilie VIENNOIS
Binghe Wang
Danzhu WANG
Yueqin Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia State University Research Foundation Inc
Original Assignee
Georgia State University Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia State University Research Foundation Inc filed Critical Georgia State University Research Foundation Inc
Publication of AU2015274767A1 publication Critical patent/AU2015274767A1/en
Application granted granted Critical
Publication of AU2015274767B2 publication Critical patent/AU2015274767B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/40—Carbon monoxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B37/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving either the formation of a carbon-to-carbon bond between two carbon atoms not directly linked already or the disconnection of two directly linked carbon atoms
    • C07B37/10—Cyclisation
    • C07B37/12—Diels-Alder reactions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2015274767A 2014-06-09 2015-06-09 Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof Ceased AU2015274767B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462009451P 2014-06-09 2014-06-09
US62/009,451 2014-06-09
PCT/US2015/034948 WO2015191616A1 (en) 2014-06-09 2015-06-09 Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof

Publications (2)

Publication Number Publication Date
AU2015274767A1 AU2015274767A1 (en) 2017-01-05
AU2015274767B2 true AU2015274767B2 (en) 2020-04-16

Family

ID=54834205

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015274767A Ceased AU2015274767B2 (en) 2014-06-09 2015-06-09 Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof

Country Status (8)

Country Link
US (2) US10300069B2 (enExample)
EP (1) EP3151919B1 (enExample)
JP (1) JP6670763B2 (enExample)
KR (1) KR20170007857A (enExample)
CN (1) CN106794362B (enExample)
AU (1) AU2015274767B2 (enExample)
CA (1) CA2950007A1 (enExample)
WO (1) WO2015191616A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794362B (zh) 2014-06-09 2021-07-06 乔治亚州立大学研究基金会股份有限公司 用于治疗应用的一氧化碳-释放分子及其制备和使用方法
WO2018093924A1 (en) * 2016-11-16 2018-05-24 Georgia State University Research Foundation, Inc. Carbon monoxide-releasing molecules and therapeutic applications thereof
KR102373273B1 (ko) * 2017-04-18 2022-03-15 기초과학연구원 고분자형 젤과 이의 제조방법, 및 이를 포함하는 물품
CN110944629B (zh) * 2017-06-12 2024-04-09 乔治亚州立大学研究基金会股份有限公司 酶触发的一氧化碳释放分子
US20180369278A1 (en) * 2017-06-23 2018-12-27 The Regents Of The University Of Michigan Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease
WO2019032879A1 (en) * 2017-08-09 2019-02-14 Georgia State University Research Foundation, Inc. CARBON MONOXIDE RELEASE MOLECULES DISCHARGED BY PHYSIOLOGICAL STIMULI
WO2019084323A1 (en) * 2017-10-25 2019-05-02 Georgia State University Research Foundation, Inc. CHEMICAL RELEASE SYSTEM DELIVERED BY ENRICHMENT
CN109306049B (zh) * 2018-09-28 2020-12-01 中国热带农业科学院农产品加工研究所 植物油-壳聚糖基可生物降解pua及其制备方法和应用
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
CN113559071B (zh) * 2021-08-18 2022-12-27 苏州大学 一种co靶向递送系统及其构建方法与应用
EP4275682A1 (en) * 2022-05-12 2023-11-15 Institut National De La Sante Et De La Recherche Medicale - Inserm Carbon monoxide-releasing molecule (corm) or composition thereof for use in the treatment or the prevention of an intestinal dysbiosis in a subject
WO2025090901A1 (en) * 2023-10-26 2025-05-01 Georgia State University Research Foundation, Inc. Ros-activated co prodrugs for cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670664A (en) * 1995-09-08 1997-09-23 University Of Maryland Biotechnology Institute Photosensitive organic compounds that release carbon monoxide upon illumination

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519928A (ja) 2002-02-04 2005-07-07 ハース，ベルナー Ｃｏ放出能力を有する化合物の投与によって哺乳動物を治療する方法と、ｃｏ放出能力を有する化合物ならびにその医薬組成物
PT1812031E (pt) 2004-11-01 2015-10-01 Univ California Composições e métodos para modificação de biomoléculas
US8519122B2 (en) 2010-02-12 2013-08-27 The Regents Of The University Of California Compositions and methods for modification of biomolecules
CN106794362B (zh) 2014-06-09 2021-07-06 乔治亚州立大学研究基金会股份有限公司 用于治疗应用的一氧化碳-释放分子及其制备和使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670664A (en) * 1995-09-08 1997-09-23 University Of Maryland Biotechnology Institute Photosensitive organic compounds that release carbon monoxide upon illumination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KITAMURA et al., "A New Hypervalent Iodine Precursor of a Highly Strained Cyclic Alkyne. Generation and Trapping Reactions of Bicyclo[2.2.1]hept-2-en-5-yne", Journal of Organic Chemistry, (1999), vol. 64, pages 680 - 681 *

Also Published As

Publication number Publication date
WO2015191616A1 (en) 2015-12-17
CN106794362B (zh) 2021-07-06
US10751344B2 (en) 2020-08-25
JP6670763B2 (ja) 2020-03-25
EP3151919A4 (en) 2018-02-21
US20170128456A1 (en) 2017-05-11
AU2015274767A1 (en) 2017-01-05
EP3151919B1 (en) 2023-08-30
US10300069B2 (en) 2019-05-28
CA2950007A1 (en) 2015-12-17
EP3151919A1 (en) 2017-04-12
JP2017528416A (ja) 2017-09-28
KR20170007857A (ko) 2017-01-20
CN106794362A (zh) 2017-05-31
US20190350937A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
AU2015274767B2 (en) Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof
US11420994B2 (en) Carbon-monoxide-releasing molecules and therapeutic applications thereof
JP6871864B2 (ja) イソオキサゾリル置換ベンズイミダゾール類
CN107750251B (zh) 异噁唑基取代的咪唑并吡啶
AU2009308511B2 (en) Transition metal complexes of a bis[thiohydrazide amide] compound
CN115066231A (zh) 合成组织屏障及其用途
TW201039815A (en) Compositions and methods for the treatment of inflammation
WO2006097625A1 (fr) NOUVEAUX DÉRIVÉS D'IMIDAZO[1,5-a]PYRIDINES, LEUR PROCÉDÉ DE PRÉPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT.
KR20210102887A (ko) 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
US20240398737A1 (en) Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
EP2958569B1 (fr) Hétérocycles phosphorés analogues de sucres à activité antimétastatique
US11730712B2 (en) Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
ES2382000T3 (es) Profármacos de carbomato de aciloxialquilo, procedimientos de síntesis y uso
WO2004080455A1 (ja) 抗菌剤と抗ガン剤
EP3237015B1 (fr) Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine
CN114478318A (zh) 二腈异佛尔酮衍生物、其制备方法及应用
JP2019516725A (ja) がんを処置するためのプロパルギル基を含む生体直交型化合物
WO2024247648A1 (ja) 腫瘍の治療剤及び複合体
CN116731305A (zh) 一种抗肿瘤大环内酯聚合物及其制备方法和应用
CN119977961A (zh) 一种protac化合物及其制备方法和作为靶向tau的降解剂的应用
CN116731307A (zh) 一种大环内酯聚合物及其制备方法与抑制促炎细胞因子作用的应用
CN116726010A (zh) 一种大环内酯衍生物在制备抑制促炎细胞因子作用剂药物的应用
JP2018535231A (ja) チアジアゾール誘導体類のｄｐｐ−ｉｖ阻害剤の結晶及びその使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired